Head-to-head · Cost-Efficiency Index
FeelGood vs PlushCare
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
FeelGood
Cost-first shoppers who want a low compounded-injection entry price with an oral tablet alternative for needle-averse shoppers.
Visit FeelGoodPlushCare
Patients who want a real board-certified physician managing GLP-1s alongside general primary care, and are prepared to navigate insurance or a manufacturer cash-pay program rather than a single flat price.
Visit PlushCareThe verdict
FeelGood and PlushCare tie on the Cost-Efficiency Index at 65/100, so neither wins outright on the numbers. For most shoppers we'd start with FeelGood (ranked #162, a hair above #166) — Cost-first shoppers who want a low compounded-injection entry price with an oral tablet alternative for needle-averse shoppers. But PlushCare is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs FeelGood.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | FeelGood | PlushCare |
|---|---|---|
| Cost-Efficiency Index | 65/100 | 65/100 |
| Semaglutide / mo | Not disclosed | $199/mo (0.25 mg dose, plus a separate fee, brand-name) |
| Tirzepatide / mo | $149/mo (starting dose, compounded) | $399/mo (5 mg dose, plus a separate fee, compounded) |
| Semaglutide / yr (modeled) | — | $2,388 |
| Tirzepatide / yr (modeled) | $1,788 | $4,788 |
| Coverage | Coverage not published | All 50 states |
| Oral / sublingual | Yes | No |
| Brand-name access | Yes | Yes |
| Rank here | #162 | #166 |
FeelGood
65/100Where the value is
- Low advertised compounded-injection entry price ($149/mo) with no stated membership or hidden fees
- Oral/dissolvable tablet option available for needle-averse patients ($249/mo)
- Free shipping and HSA/FSA eligibility stated plainly on the homepage
The tradeoffs
- Per-dose pricing, states served, named medical director, and named compounding pharmacy are all gated behind the intake questionnaire — none are disclosed on the public site, so I could not independently verify them
- It is unclear from the public site whether tirzepatide is priced the same as semaglutide or separately
PlushCare
65/100Where the value is
- Board-certified physicians (not NP-only) available in all 50 states for general virtual primary care
- Publishes an unusually granular compounded-tirzepatide dose ladder ($399/$599/$749 by vial count) instead of a vague single 'starting at' figure
- Brand Wegovy via NovoCare's manufacturer program can beat most compounded prices ($199-399/mo) when the promotion is genuinely still active
The tradeoffs
- Compounded tirzepatide and semaglutide are each only available in about 39 states plus DC, narrower than PlushCare's general 50-state telehealth business
- A $19.99/mo membership and, for uninsured patients, a $129 visit fee sit on top of every medication price and are easy to miss from the headline drug price alone
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.